-+ 0.00%
-+ 0.00%
-+ 0.00%

MacroGenics raih pembayaran USD 10 juta usai Gilead ambil lisensi program bispesifik praklinis

PUBT·08/11/2026 20:11:27
Listen to the news
MacroGenics raih pembayaran USD 10 juta usai Gilead ambil lisensi program bispesifik praklinis
  • MacroGenics mengantongi pembayaran USD 10 juta usai Gilead mengeksekusi opsi lisensi eksklusif program bispesifik praklinis.
  • Program berplatform TRIDENT itu menargetkan dua target yang tidak diungkap untuk terapi tumor solid.
  • Dalam kolaborasi 2022, kedua pihak mengembangkan tiga program, termasuk MGD024 (CD123 × CD3) tahap klinis.
  • MacroGenics masih berpeluang meraih hingga sekitar USD 1,6 miliar dalam milestone pengembangan, regulatori, komersial, serta royalti penjualan global.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111605PRIMZONEFULLFEED9808019) on August 11, 2026, and is solely responsible for the information contained therein.